Skip to main content

Consultation: Kava pilot phase 1: Allowing the importation of kava for personal use

Consultation period
-
Last updated

This consultation closed on 22 March 2019.

Invitation to comment

The Office of Drug Control sought comments from interested parties on the options concerning the announcement by the Prime Minister, the Hon Scott Morrison MP, to put together a pilot program to ease some of the limitations on importation of kava into Australia for personal use.

The consultation sought feedback on:

  • A proposal to increase the quantity of kava that may be imported for personal use to 4kg
  • Approach to evaluate the pilot program after two years; and
  • The duration of the pilot program.

Timetable

Interested parties should respond by close of business 22 March 2019.

Feedback will be released following consideration of submissions. (See What will happen).

About the consultation

On the 16 January 2019, the Prime Minister announced a pilot program would be put together to ease some of the restrictions on importation of kava, for personal use, into Australia.

The consultation paper has been prepared to enable interested parties to provide feedback on the pilot.

Content of submissions

Submissions may address any, or all, of the Pilot Program to ease restrictions on the importation of kava for personal use, or other identified issues.

In addition, submissions might include:

  • Suggested improvements.
  • Whether or not you support the proposal, including suggestions for alternatives.
  • An assessment of how the proposal will affect you.

Enquiries

Any questions relating to submissions should be directed to the Narcotics Control Section by email to ncs@health.gov.au.

What will happen

All submissions will be placed on this website unless marked confidential or indicated otherwise in the submission form (see Privacy information).

The feedback on the consultation paper will be used to inform decisions on the pilot plan to ease some of the limitations on importation of kava into Australia for personal use.

Privacy information

  • The ODC collects your personal information in this submission in order to:
    • contact you if the ODC wants to seek clarification of issues raised in your submission or to check whether you consent to certain information that you have provided being made publicly available.
    • help provide context about your submission (e.g. to determine whether you are an individual or a director of a company or representing an interest group).
    • seek feedback about how the consultation was undertaken.
  • Please do not include personal information about other individuals in the body of your submission. Personal information in this context means information or an opinion about an individual whose identity is apparent, or can reasonably be ascertained, from the information or opinion.
  • More information on privacy can be found on our website.

Submissions received

  • Consultation submission: Aboriginal Medical Services Alliance NT
  • Consultation submission: Aboriginal Resource and Development Services
  • Consultation submission: Anonymous 1
  • Consultation submission: Anonymous 2
  • Consultation submission: Anonymous 3
  • Consultation submission: Anonymous 4
  • Consultation submission: Anonymous 5
  • Consultation submission: Anonymous 6
  • Consultation submission: Anonymous 7
  • Consultation submission: Anonymous 8
  • Consultation submission: Anonymous 9
  • Consultation submission: Anonymous 10
  • Consultation submission: Anonymous 11
  • Consultation submission: Anonymous 12
  • Consultation submission: Anonymous 13
  • Consultation submission: Anonymous 14
  • Consultation submission: Anonymous 15
  • Consultation submission: Anonymous 16
  • Consultation submission: Anonymous 17
  • Consultation submission: Anonymous 18
  • Consultation submission: Anonymous 19
  • Consultation submission: Anonymous 20
  • Consultation submission: Anonymous 21
  • Consultation submission: Anonymous 22
  • Consultation submission: Anonymous 23
  • Consultation submission: Anonymous 24
  • Consultation submission: Anonymous 25
  • Consultation submission: Anonymous 26
  • Consultation submission: Anonymous 27
  • Consultation submission: Anonymous 28
  • Consultation submission: Anonymous 29
  • Consultation submission: Anonymous 30
  • Consultation submission: Anonymous 31
  • Consultation submission: Anonymous 32
  • Consultation submission: Dr S Apo Aproosa
  • Consultation submission: Biosecurity Authority Fiji
  • Consultation submission: Brisbane Tongan Community Inc.
  • Consultation submission: Mr Nilesh Chand
  • Consultation submission: Fine Foods Ltd
  • Consultation submission: Government of the Republic of Vanuatu
  • Consultation submission: Henry Hori
  • Pulotu Lyndon Chu Ling, Chief Executive Office National Codex Committee, Ministry of Commerce, Industry and Labour Samoa
  • Consultation submission: Feloko a Maui
  • Consultation submission: Ministry for Agriculture Fiji
  • Consultation submission: Ministry of Commerce Industry and Labour
  • Consultation submission: National Drug Research Institute
  • Consultation submission: Northern Territory Council of Social Service
  • Consultation submission: Dr Haunga Petelo
  • Ardimulam Pillay, Medical Practitioner
  • Consultation submission: Jitoko Sisaro
  • Professor Jerome Sarris, NICM Health Research Institute, Western Sydney University
  • Consultation submission: Vanuatu Kava Industry Association
  • Consultation submission: Mrs Kingi Vunipola

View submissions

Audiences
  • Importers
  • Travellers
Topics

Help us improve the Office of Drug Control site